Fundraising FoxWoodford Investment Management
Venture capitalOxford · Series A–Growth
Also known as Woodford Asset Management Limited
Find your way into Woodford Investment Management
What they invest in
from 4 of 5 portfolio companiesBiotech ×3Healthtech ×2Digital Health ×1Travel & Hospitality ×1Wellness & Fitness ×1
HQs:United States×2United Kingdom×1
Investments · 5 tracked
founders shown can be your intro pathBy year:2020 · 12019 · 12017 · 13 dated
Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis.
BiotechSan Diego, US
Ivy Zhang(Executive Officer)inSaundra Pelletier(Executive Officer, Director)inKelly Culwell(Executive Officer)inJustin J. File(Executive Officer)inAlexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)
Co-investorsAdjuvant CapitalDomain AssociatesInvesco
Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO.
BiotechHealthtechLondon, GB
John Richard(Head of Corporate Development and Co-Founder)inCharles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)inJill Henrich(Senior Vice President)inDenise Scots-Knight(Chief Executive Officer)in
BoardDr. Deepa Pakianathan(Non-Executive Director)
Co-investorsCancer FocusPontifax Venture CapitalVivo Capital
Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.
Digital HealthHealthtechTravel & HospitalityWellness & Fitness
Co-investorsAstellas Venture Management LLCHatteras Venture PartnersLilly VenturesNovartis Venture Fund
Mobile payment and loyalty platform, powering apps such as the Caffe Nero app in the UK and Ireland.
Co-investorsFirestartrLeadX Capital PartnersMetro Group
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 2
2 IPOsEvofem BiosciencesOTC: EVFMMereo BioPharma GroupNASDAQ: MREO
Principals & officers · per Companies House
what is this? ⓘDirector · British · since 2016
Craig Frederick Newman — 25–50% of shares, 25–50% of voting rights
Neil Russell Woodford — 50–75% of shares, 50–75% of voting rights
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Evofem Biosciences | 42.0% | $4.69 | May 2018 | $35M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Woodford Investment Management made?
- Woodford Investment Management has 5 tracked investments, 2 of which have exited.
- What stage does Woodford Investment Management invest at?
- Woodford Investment Management invests at the Series A, Series B, Series C, Growth stages.
- What sectors does Woodford Investment Management focus on?
- Woodford Investment Management focuses on Biotech, Healthtech, IoT, Medical Devices.
- Where is Woodford Investment Management located?
- Woodford Investment Management is headquartered in Oxford, GB.
Similar investors
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
Olive Tree Capital is a venture capital firm that invests in founders building at the technological frontier.
Industrial Technology Investment Corporation is the venture capital arm of Taiwan's Industrial Technology Research Institute (ITRI), backing startups across multiple stages and sectors while providing access to ITRI's R&D resources.